ACCORD DE LICENCE EUROPEEN AVEC WATSON PHARMACEUTICALS INC. (U.S.A.) POUR KENTERA® | Bourse Reflex
Accueil > Actualités > Communiqués

ACCORD DE LICENCE EUROPEEN AVEC WATSON PHARMACEUTICALS INC. (U.S.A.) POUR KENTERA®

Jeudi 17 Jan 2008 à 12:22

RECORDATI : ACCORD DE LICENCE EUROPEEN AVEC WATSON PHARMACEUTICALS INC. (U.S.A.) POUR KENTERA®

Milan, le 16 janvier 2008 - Recordati a annoncé la signature d'un accord de licence exclusif avec une filiale de Watson Pharmaceuticals, Inc.(NYSE: WPI), une société pharmaceutique nord-américaine, pour le marketing et la vente dans 29 pays en Europe de Kentera®, un patch transdermique à base d'oxybutinine qui s'applique deux fois par semaine pour le traitement symptomatique de l'incontinence et/ou de l'augmentation de la fréquence des mictions (besoin fréquent d'uriner) et de l'impériosité urinaire (besoin immédiat d'uriner). Kentera® a été approuvé par l'Agence Européenne des Médicaments (EMEA) dans le cadre de la procédure centralisée en 2004. Commercialisé dans de nombreux pays, les ventes actuelles s'élèvent à plus de 7 millions d'euros.

The incidence of micturition disorders, and overactive bladder (OAB) in particular, is increasing in the industrialized world. However, OAB remains under-diagnosed and under-treated. Therefore, there is a significant potential for growth in this market for products with proven efficacy and improved tolerability. "The acquisition of Kentera®, an original system for the administration of a well-known drug improving its tolerability profile, reinforces Recordati's focus in the urology area where it is developing silodosin, indicated for the treatment of benign prostate hypertrophy, due for filing in Europe in the second half of 2008" declared Giovanni Recordati, Chairman and CEO.

Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, isin IT 0003828271), dedicated to the research, development, manufacturing and marketing of pharmaceuticals, with headquarters in Milan, Italy, operations in the main European countries, and a total staff of over 2,200. A European field force of over 1,100 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas. Recordati's current and growing coverage of the European pharmaceutical market makes it a partner of choice for new product licenses from companies which do not have European marketing organizations. Recordati is committed to the research of new drug entities within the cardiovascular and urogenital therapeutic areas in which its research TEAM has proven scientific competence and a track record of discovery and development of original drugs, the most recent of which, lercanidipine, a latest generation calcium channel blocker for the treatment of hypertension, is the company's leading product. Consolidated revenue for 2006 was E 576.2 million, operating income was E 120.3 million and net income was E 74.0 million.

For further information:

Recordati website: www.recordati.com

Investor Relations

Marianne Tatschke

(39)0248787393

e-mail: inver@recordati.it

Media Relations

Claudio Rossetti (Echo Comunicazione d'Impresa)

(39)0262694736

e-mail: crossetti@echocom.it

Statements contained in this release, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intended to indicate the advisability of administering any product in any particular instance.

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

VIA M. CIVITALI, 1 - 20148 MILANO, ITALY - TEL (39) 02 48787.1 - FAX (39) 02 40073747

Copyright Hugin

[CN#130995]

Partager sur Facebook
Article Précédent :
Déclaration des transactions sur...
Article Suivant :
Access Commerce gratifié d'une...

Ecrire un commentaire

J'accepte la charte et que mon commentaire soit publié sur BourseReflex.com 

Les autres actualités


Retour vers 'Communiqués' »




Mots-clés : Euros   Watson   European   Italy   Income   Looking   Assumptions  
Sociétés citées dans cette news : TEAM  

Si vous passez un ordre de bourse sur le CAC40 le vendredi soir à 18h, quand sera t-il éxécuté?
Mon portefeuille virtuel

Initiez-vous à la gestion gratuitement et sans risque !

Ma liste de valeurs

Suivez l'évolution du cours de vos valeurs préférées !

Alerte email

Soyez immediatement informés


Retrait de Borloo
Jean-Louis Borloo a décidé de ne pas se porter candidat à l'élection présidentielle de 2012. Qu'en pensez-vous?